LAM-001

Phase 2Small molecule

OOrphAI Therapeutics

LAM-001 is one of 61 small molecule programs targeting Bronchiolitis Obliterans. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchiolitis ObliteransActive, not recruiting

Pulmonary HypertensionActive, not recruiting

Pulmonary Hypertension Due to Lung DiseasesRecruiting

Bronchiolitis ObliteransPhase 2

Active, not recruiting

Pulmonary HypertensionPhase 2

Active, not recruiting

Pulmonary Hypertension Due to Lung DiseasesPhase 2

Recruiting

Competition

Competitive Landscape

154 competitors in Pulmonary Hypertension

#DrugCompanyPhaseTrials

Reata

Biogen

Phase 3

2 2

Diamox

Teva

Phase 3

2 3

Lexapro

AbbVie

Phase 3

1 4

Crestor

AstraZeneca

Phase 3

1 5

Accrufer

SShield Therapeutics

Phase 3

1 6

Zesly

MMezzion Pharma Co. Ltd

Phase 3

1 7

Distilled Water

GSK

Phase 3

2 8

Diluent

Sanofi

Phase 3

1 9

Remodulin

United Therapeutics

Phase 3

1 10

Iloprost Inhalation

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Bronchiolitis Obliterans

NCT06018766

Q3 2028

Phase 2Recruiting

Pulmonary Hypertension Due to Lung Diseases

NCT05798923

Clinical

Trials by Indication[1]

Bronchiolitis Obliterans1 trial

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

Recruiting·SSteven Hays, MD·Phase 2·NCT06018766·30 enrolled

Pulmonary Hypertension Due to Lung Diseases1 trial

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Recruiting·OOrphAI Therapeutics·Phase 2·NCT05798923·85 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LAM-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LAM-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LAM-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OrphAI Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOrphAI Therapeutics

LAM-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2028

Trials by Indication[1]

Bronchiolitis Obliterans1 trial

Pulmonary Hypertension Due to Lung Diseases1 trial

References

Drug Info

Quick Facts

Related News